Strategic Partnerships Medlogics is developing a next generation drug eluting stent platform with a novel stent and drug delivery approach, creating opportunities for licensing or co development with larger cardiovascular device companies.

Vertical Integration Advantage With in house drug eluting coating, stent and catheter R&D and manufacturing, the company can offer contract manufacturing or technology transfer to other medtech players seeking specialized coatings.

Growth Readiness The company's current scale suggests opportunities to partner on scale manufacturing, automation, and quality systems to support regulatory milestones and wider market adoption.

Market Focus Focused on coronary artery disease therapy with drug eluting devices, the target buyers include hospitals and cardiology departments; there is potential to engage hospital groups, distributors, and procurement teams.

Competitive Positioning In a market led by large incumbents, Medlogics can position as an agile specialist offering unique coating capabilities and faster collaboration for co development or supply agreements.